ipamorelin
Small moleculeexperimental
Ipamorelin (INN; development code NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00672074)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Growth hormone receptorAGONIST
GHR agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O- Mol. weight
- 711.87 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIpamorelin ↗
- ChEMBLCHEMBL58547 ↗
Also known as
- aib-his-2nal-phe-lys-nh2
- ipamorelin
- ipamorelin
- ipamorelin
- ipamorelin
- ipamorelin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01280344 | Phase 2 | Apr 1, 2011 | Helsinn |
| NCT00672074 | Phase 2 | Apr 1, 2008 | Helsinn |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Helsinn | For profit | 2 | 2 | 1 | 2008 |
1 organizations
Page 1 / 1